Amylyx Pharmaceuticals (AMLX) Cash from Operations (2021 - 2026)

Amylyx Pharmaceuticals' Cash from Operations history runs 6 years deep, the most recent figure standing at 36882000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 7.39% year-over-year to 36882000.0; the TTM figure through Mar 2026 stood at 120401000.0 (up 41.83% YoY), while the FY2025 annual figure was 123343000.0, up 26.43% from the prior year.
• Cash from Operations was 36882000.0 for Q1 2026 at Amylyx Pharmaceuticals, down from 27903000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 13551000.0 in Q4 2023 to a low of 66580000.0 in Q2 2024.
• Historically, Cash from Operations has averaged 29166117.65 across 5 years, with a median of 36882000.0 in 2026.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations surged 127.27% in 2023, then sank 8043.97% in 2025.
• A 5-year view of Cash from Operations shows it stood at 49697000.0 in 2022, then jumped by 127.27% to 13551000.0 in 2023, then plunged by 535.45% to 59008000.0 in 2024, then jumped by 52.71% to 27903000.0 in 2025, then slumped by 32.18% to 36882000.0 in 2026.
• The last three Cash from Operations figures came in at 36882000.0 (Q1 2026), 27903000.0 (Q4 2025), and 30368000.0 (Q3 2025), per Business Quant data.